Renin-Angiotensin System Implications to COVID-19 Comorbidities

Area of Science:

• Cardiovascular Science
• Infectious Diseases
• Molecular Biology

Background:

• The renin-angiotensin system (RAS) and its modulators are under scrutiny for their role in COVID-19 susceptibility and outcomes.
• Angiotensin-converting enzyme type 2 (ACE2) is a key focus, acting as the SARS-CoV-2 virus receptor and regulating angiotensin II effects.
• ACE2 provides anti-inflammatory and antifibrotic protection to organs, balancing angiotensin II's actions.

Purpose of the Study:

• To review the involvement of ACE2 and alternative RAS pathways in COVID-19 comorbidities.
• To explore the link between RAS components and the clinical manifestations of COVID-19.

Main Methods:

• Literature review of recent studies on RAS, ACE2, and COVID-19.
• Analysis of the dual role of ACE2 as a viral entry receptor and a protective enzyme.
• Discussion of potential implications for comorbidities and clinical outcomes in COVID-19 patients.

Main Results:

• ACE2's dual function as the SARS-CoV-2 receptor and a regulator of the RAS is central to COVID-19 pathogenesis.
• Dysregulation of the RAS, potentially involving ACE2, may contribute to the diverse comorbidities observed in COVID-19.
• Alternative RAS pathways might also influence disease severity and organ-specific damage.

Conclusions:

• ACE2 and the broader RAS network are significantly implicated in COVID-19.
• Further research into ACE2 and RAS pathways is essential for understanding COVID-19 comorbidities and developing targeted therapies.
• Targeting the RAS may offer therapeutic strategies for managing COVID-19 complications.